Allergan Inc., of Irvine, Calif., said Botox (onabotulinumtoxinA) received a license from the UK’s Medicines and Healthcare products Regulatory Agency for the temporary improvement in the appearance of moderate to severe lateral canthal lines (crow’s feet lines) seen at maximum smile, either alone or when treated at the same time as glabellar (or frown) lines seen at maximum frown, in adult patients where those facial lines have an important psychological impact. Read More
Altheus Therapeutics Inc., of Oklahoma City, said it completed enrollment for ZA201, a six-week, double-blind, active-controlled Phase II trial of the efficacy and safety of Zoenasa rectal gel in approximately 120 adult patients with left-sided, or distal, ulcerative colitis. Read More
Mallinkrodt Inc., of St. Louis, and Zogenix Inc., of San Diego, said they mutually agreed to end their co-promotion agreement covering Sumavel Dosepro (sumatriptan injection), a needle-free delivery of the migraine drug. Read More
Cancer Prevention Pharmaceuticals Inc. and Swiss specialty pharma company Tillotts Pharma AG, a wholly owned subsidiary of Tokyo-based Zeria Pharmaceutical Co. Ltd., signed a licensing agreement for European and Japanese rights to develop and commercialize CPP-1X/sulindac for the treatment of the orphan disease familial adenomatous polyposis, and other gastrointestinal conditions. Read More
Three large financings, including another initial public offering (IPO), and a flurry of smaller deals in the first full week of the New Year – and on the eve of the bellwether J.P. Morgan Healthcare Conference in San Francisco – signaled that money is continuing to flow into biotech in a big way. Read More
Transgene SA was riding high Thursday after releasing top-line preliminary data from a Phase IIb/III study of TG4010, an immunotherapy being developed for non-small-cell lung cancer (NSCLC). Read More
AC Immune SA raised CHF20 million (US$22 million) in a Series D round that will fund clinical development of a therapeutic vaccine for Alzheimer’s disease, ACI-35, which targets a phosphorylated species of tau protein thought to be involved in the progression of the condition. Read More
A month after reporting promising preclinical data from its zinc finger nuclease (ZFN) therapy in beta-thalassemia at the American Society of Hematology (ASH) meeting in New Orleans, Sangamo Biosciences Inc. licensed rights to the technology in a collaboration with Biogen Idec Inc. worth up to about $314 million total. Read More
Avillon Group, of London, said it entered an exclusive collaborative development agreement with Pfizer Inc., of New York, to conduct a Phase III trial of Bosulif (bosutinib). Read More
